Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in RNA held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Transmarket Holdings LP | 20K | $1.4M | — | 0.114% | 0.43% |
| 2 | BLUEFIN CAPITAL MANAGEMENT, LLC | 10K | $721K | — | 0.059% | 0.09% |
| 3 | Marex Group plc | 10K | $455K | +193.7% | 0.058% | 0.00% |
| 4 | Z3 Capital Partners, LLC | 4K | $274K | — | 0.022% | 0.03% |
| 5 | Corsicana & Co. | 8K | $236K | 0.0% | 0.047% | 0.15% |
| 6 | Byrne Asset Management LLC | 177 | $2K | -90.0% | 0.001% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in RNA — a direct measure of their conviction.
Filings activity in RNA during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 6 | 98% | 1.46% | 198.53 pp | $3M | 100% |
| Q4 2025 | 334 | +25% | 199.99% | +0.00 pp | $9.93B | +51% |
| Q3 2025 | 267 | +28% | 199.99% | +0.00 pp | $6.57B | +87% |
| Q2 2025 | 208 | 4.1% | 199.99% | +0.00 pp | $3.51B | 1.9% |
| Q1 2025 | 217 | 6.5% | 199.99% | +0.00 pp | $3.58B | +6.8% |
| Q4 2024 | 232 | 3.7% | 199.99% | +0.00 pp | $3.36B | 36% |
| Q3 2024 | 241 | +23% | 199.99% | +0.00 pp | $5.22B | +27% |
| Q2 2024 | 196 | — | 199.99% | — | $4.09B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying RNA stock.
Based on Q1 2026 13F filings, institutional ownership of Atrium Therapeutics, Inc. stands at 1.5%, held across 6 reporting institutions.
Transmarket Holdings LP is the largest reported institutional holder of RNA, with approximately 19,537 shares worth $0.00B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of RNA.
Our composite Smart Money Score for RNA is 0 out of 100 (Heavy Distribution). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in RNA during Q1 2026, while 331 fully exited. 1 added to existing positions and 2 trimmed.
RNA institutional ownership fell by 198.53 percentage points quarter-over-quarter, with a net change of -328 holders.
The top 10 institutions account for 100.0% of all reported 13F value in RNA, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Atrium Therapeutics, Inc. (RNA) Institutional Ownership